Non-Hodgkin Lymphoma | Specialty

CAR-T Treatment Options for R/R DLBCL

February 26th 2021

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies

February 26th 2021

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

Time-Limited Therapy Takes Center Stage in Frontline and Relapsed/Refractory CLL

February 24th 2021

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia, made possible by agents such as venetoclax, umbralisib, and lisocabtagene maraleucel.

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

February 24th 2021

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

The Future of Chronic Lymphocytic Leukemia Treatment

February 24th 2021

Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.

Treatment Sequencing in Chronic Lymphocytic Leukemia

February 24th 2021

Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.

Final GENUINE Data Support Addition of Ublituximab to BTK Inhibitors in Relapsed/Refractory, High-Risk CLL

February 23rd 2021

Feburary 23, 2021 — The addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone with acceptable safety in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

R/R Follicular Lymphoma: Second-line Treatment Selection

February 22nd 2021

Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.

R/R Follicular Lymphoma: Patient Prognosis

February 22nd 2021

Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.

CAR T-Cell Therapy for R/R DLBCL

February 19th 2021

Novel Therapies for R/R DLBCL

February 19th 2021

Giants of Cancer Care Honorees June and Rosenberg Receive Prestigious Prize

February 17th 2021

February 17, 2021 - Carl H. June, MD, and Steven A. Rosenberg, MD, PhD, have received the 2021 Dan David Prize Laureate for their research in oncology. They, along with Zelig Eshhar, an immunologist at the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center, will share a prize of $1 million.

FDA Accepts Application for Zanubrutinib in Waldenström Macroglobulinemia

February 17th 2021

February 17, 2021 — The FDA has accepted a supplemental new drug application of zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Activity in B-Cell NHL

February 17th 2021

February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.

Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia

February 17th 2021

Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.

Chronic Lymphocytic Leukemia Treatment Considerations 

February 17th 2021

Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.

Targeted Therapies Reign in the Frontline Treatment of CLL

February 16th 2021

Jacqueline Claudia Barrientos, MD, MS, explaines how she navigates among the options available in the frontline setting for patients with CLL and highlighted ongoing research efforts of interest.

Braunschweig Makes the Case for Earlier Use of CAR T-Cell Therapy in DLBCL

February 16th 2021

CAR T-cell therapy has shown robust responses and curative potential in patients with diffuse large B-cell lymphoma, regardless of cytogenetics or age.

Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL

February 15th 2021

Narendranath Epperla, MD, MS, expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.